Analysis population and patient flow. benda, bendamustine; CVP, cyclophosphamide, vincristine, prednisone; G, obinutuzumab; MZL, marginal zone lymphoma; R, rituximab. *The 2 patients with HBV reactivation who had received prophylactic NAT had their study treatment withheld until their HBV DNA returned to undetectable levels; neither patient developed HBV-related hepatitis. †None of 25 patients with HBV reactivation who were treated with preemptive NAT developed HBV-related hepatitis.